Literature DB >> 30950326

MiR-125b regulates the proliferation and metastasis of triple negative breast cancer cells via the Wnt/β-catenin pathway and EMT.

Jun Nie1, Hong-Chao Jiang2, Yong-Chun Zhou1, Bo Jiang1, Wen-Jie He1, Yu-Feng Wang1, Jian Dong3.   

Abstract

BACKGROUND/AIM: MiR-125b plays an important role in breast cancer. The current study was to explore the expression and function of miR-125b in triple negative breast cancer cells.
MATERIALS AND METHODS: The expression of miR-125b in human TNBC samples and cell lines were examined by qRT-PCR. MTT, scratch assays and transwell assays were utilized to observe the proliferation, migration and invasion ability. MiR-125b's target gene and downstream signaling pathways were investigated by Luciferase Reporter Assays, qRT-PCR, immunofluorescence assays and western bolt.
RESULTS: MiR-125b was highly expressed in human TNBC tissues and cell lines. Inhibiting miR-125b expression suppressed the proliferation, cell migration and invasion. The three-prime untranslated region (3´-UTR) of adenomatous polyposis coli (APC) mRNA contains miR-125b binding sites, and inhibiting miR-125b expression suppressed the activity of the intracellular Wnt/β-catenin pathways and EMT.
CONCLUSION: Inhibiting miR-125b regulates the Wnt/β-catenin pathway and EMT to suppress the proliferation and migration of MDA-MB-468 TNBC cells.

Entities:  

Keywords:  TNBC; Wnt/β-catenin; metastasis; miR-125b; proliferation

Mesh:

Substances:

Year:  2019        PMID: 30950326     DOI: 10.1080/09168451.2019.1584521

Source DB:  PubMed          Journal:  Biosci Biotechnol Biochem        ISSN: 0916-8451            Impact factor:   2.043


  14 in total

Review 1.  Role of microRNA/lncRNA Intertwined With the Wnt/β-Catenin Axis in Regulating the Pathogenesis of Triple-Negative Breast Cancer.

Authors:  Xue Hu; Qiang Zhang; Wanying Xing; Wan Wang
Journal:  Front Pharmacol       Date:  2022-06-24       Impact factor: 5.988

Review 2.  The functional significance and cross-talk of non-coding RNAs in triple negative and quadruple negative breast cancer.

Authors:  Utpalendu Paul; Satarupa Banerjee
Journal:  Mol Biol Rep       Date:  2022-03-02       Impact factor: 2.742

Review 3.  MicroRNAs Involved in Carcinogenesis, Prognosis, Therapeutic Resistance and Applications in Human Triple-Negative Breast Cancer.

Authors:  Lei Ding; Huan Gu; Xianhui Xiong; Hongshun Ao; Jiaqi Cao; Wen Lin; Min Yu; Jie Lin; Qinghua Cui
Journal:  Cells       Date:  2019-11-22       Impact factor: 6.600

4.  NELFE promoted pancreatic cancer metastasis and the epithelial‑to‑mesenchymal transition by decreasing the stabilization of NDRG2 mRNA.

Authors:  Lili Han; Ying Zan; Chen Huang; Shuqun Zhang
Journal:  Int J Oncol       Date:  2019-10-02       Impact factor: 5.650

Review 5.  MicroRNAs target the Wnt/β‑catenin signaling pathway to regulate epithelial‑mesenchymal transition in cancer (Review).

Authors:  Yuhe Lei; Lei Chen; Ge Zhang; Aiyun Shan; Chunfeng Ye; Bin Liang; Jiayu Sun; Xin Liao; Changfeng Zhu; Yueyue Chen; Jing Wang; Enxin Zhang; Lijuan Deng
Journal:  Oncol Rep       Date:  2020-07-23       Impact factor: 3.906

6.  Increased expression of MUSASHI1 in epithelial breast cancer cells is due to down regulation of miR-125b.

Authors:  Mahboobeh Forouzanfar; Liana Lachinani; Kianoush Dormiani; Mohammad Hossein Nasr-Esfahani; Kamran Ghaedi
Journal:  BMC Mol Cell Biol       Date:  2021-02-04

7.  LncRNA MALAT1 Promote Cell Proliferation and Invasion by Sponging miR-125b to Modulate HMGA1 Expression in Laryngocarcinoma.

Authors:  Guangxin Zong; Xinrong Feng; Xiuhua Sun; Jiexin Du; Guangsheng Wang; Tingting Song
Journal:  Iran J Public Health       Date:  2021-05       Impact factor: 1.429

8.  MicroRNA-125b as a tumor suppressor by targeting MMP11 in breast cancer.

Authors:  Yanan Wang; Yaning Wei; Xiangyu Fan; Pei Zhang; Pan Wang; Shujie Cheng; Jinku Zhang
Journal:  Thorac Cancer       Date:  2020-04-14       Impact factor: 3.500

9.  Curcumol enhances the anti-tumor effects of metformin via suppressing epithelial-mesenchymal transition in triple-negative breast cancer.

Authors:  Gangyue Wang; Yi Dong; Heng Liu
Journal:  Ann Transl Med       Date:  2020-08

10.  Inhibition of SMYD2 suppresses tumor progression by down-regulating microRNA-125b and attenuates multi-drug resistance in renal cell carcinoma.

Authors:  Libin Yan; Beichen Ding; Haoran Liu; Yangjun Zhang; Jin Zeng; Junhui Hu; Weimin Yao; Gan Yu; Ruihua An; Zhiqiang Chen; Zhangqun Ye; Jinchun Xing; Kefeng Xiao; Lily Wu; Hua Xu
Journal:  Theranostics       Date:  2019-10-22       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.